食品与药物管理局批准Qfitlia,这是预防血友病患者出血的首种药物。 FDA approves Qfitlia, a first-of-its-kind drug for preventing bleeding in hemophilia patients.

林业发展局已核准Qfitlia方案,防止成人和12岁及12岁以上儿童的血友病A或B出血,包括有抑制剂的血友病。 The FDA has approved Qfitlia for preventing bleeding in adults and children aged 12 and older with hemophilia A or B, including those with inhibitors. Qfitlia减少抗血红素蛋白, 以增加血凝胶, 使用亚皮注射。 As a first-of-its-kind siRNA drug, Qfitlia reduces antithrombin protein to increase blood clotting, administered via subcutaneous injection. 它旨在降低出血频率,并为血友病管理提供新的治疗选择。 It aims to lower the frequency of bleeding episodes and offers a new treatment option for hemophilia management.